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ABSTRACT:  
BACKGROUND: Hypertrophic cardiomyopathy is the most frequent inheritable heart 
disease, affecting 1 in 500 people. The inheritance pattern is autosomal dominant, and 
it is caused by mutations in sarcomere protein genes, which induce ventricular 
hypertrophy that cannot be explained by loading conditions. Its way of manifestation is 
widely diverse, from asymptomatic patients to patients suffering from sudden cardiac 
death. The role of genetics is becoming increasingly important in studying the variants 
involved, their prognosis, and their role in family screening.  
 
OBJECTIVES: making a review about HCM and studying the yield of the genetic test in 
HCM population in Cantabria. 
MATERIALS AND METHODS: creation of a data base with clinical, imaging and genetic 
information of HCM proband cases in Cantabria who underwent a genetic test between 
January 2018 and January 2020,  
RESULTS: 140 patients were included (60.71% were men; mean age was 61.33 ±1.25 
years). 33 (23.57%) patients had positive test, 19 (13.57%) had VUS test and 88 studies  
(62.86%) were negative. The most frequent pathogenic variants were MYBPC3 (42.42%) 
and MYH7 (39.39%).  
DISCUSSION AND CONCLUSION: the yield of genetic test was lower than the prevalence 
of pathogenic variants described in literature (23.57% versus about 60%). There were 
no data enough to assess definitive conclusions  
KEY WORDS : Hypertrophic Cardiomyopathy, genetic test, pathogenic variants, 
diagnosis, clinical manifestations. 
RESUMEN:  
 
INTRODUCCIÓN: La miocardiopatía hipertrófica es la cardiopatía hereditaria más 
frecuente, afectando a 1 de cada 500 personas. Está producida por mutaciones en los 
genes sarcoméricos que se heredan de manera autosómica dominante, produciendo 
hipertrofia ventricular no explicable por otras causas, pudiendo no producir síntomas o 
incluso producir muerte súbita cardiaca. El estudio genético está cobrando cada vez más 
importancia a la hora de identificar las variantes, su pronóstico y su papel en el cribado 
familiar.  
 
OBJETIVOS: hacer una revisión de la literatura sobre MCH y estudiar la rentabilidad del 
restudio genético de la enfermedad en Cantabria.  
 
MATERIALES Y MÉTODOS: creación de una base de datos con las características clínicas, 
radiológicas y genéticas de los casos índice de Cantabria a los que se les realizó el estudio 
genético entre enero de 2018 y enero de 2020.  
 
RESULTADOS: se incluyeron 140 casos índice (60.71% eran hombres; la media de edad 
fue 61.33 ±1.25 años). 33 (23.57%) estudios fueron positivos, 19 (13.57%) tuvieron un 
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resultado con significado incierto y 88 (62.86%) fueron negativos. 
 
DISCUSIÓN Y CONCLUSIONES: la rentabilidad del estudio genético encontrando 
variantes patogénicas fue menor que en la literatura (23.57% frente a 60%).  No hubo 
datos suficientes para extraer conclusiones definitivas.  
 
PALABRAS CLAVE: Miocardiopatía Hipertrófica, estudio genético, variante patogénica, 
diagnóstico, manifestaciones clínicas.  
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1. INTRODUCTION  
Hypertrophic cardiomyopathy (HCM) is the most common monogenic inheritable 
cardiomyopathy, transmitted as an autosomal dominant pattern, which is clinically 
identified in 1 of 500 people. The disease is defined by the presence of increased left 
ventricular (LV) wall thickness explained by sarcomeric mutations, and not related to 
abnormal loading conditions.1, 8, 11, 13, 20 
HCM is defined by the presence of increased left ventricular (LV) wall thickness (more 
than 15 mm wall thickness by cardiac magnetic resonance, computed tomography or 
echocardiography). 11, 20  
At present, pathogenic or likely pathogenic 
variants have been identified in 60% of 
patients with HCM, which are responsible of 
deficits in sarcomere relaxation and 
consequent clinical manifestations or even 
sudden death. Over 450 mutations in 20 
sarcomere and myofilament-related proteins 
have been identified for HCM.  However, most 
mutations affect genes encoding for the β-
myosin heavy chain (MYH7) and myosin 
binding protein C (MYBPC3) of the cardiac 
sarcomere. 1, 7, 9, 11, 14, 20  
 
Patients with HCM exhibit a variable 
phenotype with ventricular hypertrophy being 
the cardinal manifestation, myocyte 
hypertrophy and disarray (figure 1) as well as 
interstitial fibrosis as key pathological 
hallmarks, and impaired ventricular filling and 
dynamic left ventricular outflow tract (LVOT) 
obstruction as important pathophysiologic 
features. 2, 6 
Current annual disease related mortality is 
estimated at 0,5% in adolescence and 
adulthood, which means it is similar to 
general population. More than 60% of the 
survivors with HCM report normal heart 
function (NYHA class I). Although sudden cardiac death (SCD) is uncommon, it is a 
devastating complication. SCD results from ventricular arrhythmias caused by 
autonomic overactivity secondary to LVOT obstruction, microvascular ischemia, 
myocardial fibrosis, and myocyte disarray. It can be treated effectively with an 
implanted cardioverter/defibrillator (ICD), which  is recommended in patients at a high 
risk of SCD based on multiple clinical factors . 2, 8, 11, 13,   
 
Figure 1. (A) Photograph of a necropsy heart at mid 
septal level from an individual with HCM. The 
hypertrophy involves both the free and septal walls 
of the left ventricle. (B) Haematoxylin and eosin 
stained section of myocyte disarray in HCM. 
Obtained from Hughes SE, McKenna WJ. «New 
insights into the pathology of inherited 
cardiomyopathy.» Heart (2005): 257-264. 
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It is important to highlight the fact that in less than 10% of cases, left ventricle 
hypertrophy not related to abnormal loading conditions is caused by mutations in genes 
related to metabolic disorders (Anderson-Fabry disease), mithocondrial 
cardiomyopathies, or neuromuscular diseases (Friedreich´s ataxia) and not directly 
related to sarcomeric mutations, which are considered as HCM phenocopies. 3, 4, 13, 20 
1.1. PATHOGENESIS  
Mutations in the genes encoding sarcomeric proteins induce several alterations in the 
protein expression, morphology and function and influences sarcomere assembly, force 
generation, intracellular calcium homeostasis, and ATPase activity. Secondary to the 
gene defect, pro-hypertrophic and pro-fibrotic signaling (e.g., TGF-β, Periostin, MEF2, 
MAPK, RAS, NFAT) are activated, and there is also an altered gene expression, post- 
translational modifications, mitochondrial dysfunction and mitotic factors. All these 
modifications lead to the histopathological changes, provoking myocite disarray and 
myocardial fibrosis, which finally manifests as left ventricle hypertrophy (LVH). HCM 
pathogenesis and its consequences are summarized in Figure 3.6, 8 
The LVH and the myofibrillar disarray and fibrosis are responsible of hemodynamic 
derangements, as prolonged and impaired ventricular relaxation, with losing chamber 
compliance and abnormal intracellular calcium use, which finally provokes the diastolic 
dysfunction theoretically present in all patients with HCM (Figure 2).8  
Narrowing of the LVOT from septal hypertrophy or abnormal subvalvular mitral 
apparatus, results in turbulent flow that “drags” the redundant mitral valve into the 
LVOT, resulting in decreased forward flow and systolic anterior motion (SAM)-mediated 
mitral regurgitation. One third of patients with HCM have LV outflow tract obstruction 
Figure 2. Scanning electron microscopy of cardiomyocytes from a normal subject (A, D) and a patient with HCM (B, 
C, E, F) are shown. Images were obtained after the removal of either connective tissue (A, B, C) or nonfibrous tissue 
(D, E, F). In the heart sample from the patient with HCM, myocardial disarray, abnormal branching, and bizarre 
myocardial hypertrophy (B, C) increased interstitial connective tissue elements (E) and thickened small intramural 
vessels, in which luminal narrowing (F) can be observed. Magnifications are x600 (A, B, F), x1000 (C), and x300 (D, 
E). Bar indicates 20 µm. Obtained from Kanzaki Y, Yamauchi Y, Okabe M, Terasaki F, Ishizaka N. «Three-Dimensional 
Architercture of Cardiomyocytes and Connective Tissues in Hypertrophic Cardiomyopathi: A Scanning Electron 
Microscopic Observatio.» Images in Cardiovascular Medicine (2012): 738-739. 
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(LVOTO), defined as LVOT gradient ≥30 mmHg as an instantaneous peak Doppler LV 
outflow tract pressure at rest or during physiological provocation such as Valsalva 
maneuver, standing and during exercise, and is dynamic in nature, a unique feature of 
HCM. The severity of the LVOTO is influenced by the ventricular volume, which in turn 
is a function of the interactions between myocardial contractility, ventricular preload 
and afterload. Increases in contractility, reductions in preload and afterload reduce 
ventricular volume and cause or intensify obstruction; one third part of HCM patients 
have that kind of obstruction remarkable only during maneuvers which disturb the 
loading conditions or the LV centrality.8, 18, 20 
Mitral regurgitation is also related to high LV filling pressures. Mitral regurgitation finally 
leads into atrial enlargement and in final steps of HCM, it can be responsible of 
pulmonary hypertension.8, 20 Furthermore, papillary muscle abnormalities such 
hypertrophy, anterior or lateral displacement and direct insertion into the anterior 
mitral valve leaflet and mitral valve alterations as elongation or tissue disturbances can 
also be responsible of increasing or helping the obstruction of the outflow tract. Those 
abnormalities in the mitral valve can also result in mitral regurgitation, which knowing 
the pathophysiology of LOVTO can make easier to understand why it is a condition 
closely related to LVOTO.11, 18, 20 
Despite LVOTO is frequently found in HCM patients, it is not specific of the disease, since 
it can be developed in other circumstances, which can be very common in general 
population, like hypertension, hypovolemia, calcification of the mitral annulus and 
situations which makes the myocardial contractility to be increased, such those 
situations which induce reflex syncope. 10, 18, 20 
 
 
 
 
Figure 3. Schematic summarizing the pathogenesis of HCM. Modified from CM, Wolf. «Hypertrophic 
cardiomyopathy: genetics and clinical perspectives.» Cardiovascular Diagnosis and Therapy (2019): 388-415 
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1.2. CLINICAL MANIFESTATIONS AND COMPLICATIONS 
Clinical manifestations of HCM are notably variable. There is a large range of 
symptomatology, as most patients are asymptomatic, whereas other suffer from sudden 
death as onset disease. Between these two possibilities, there is a wide variety of 
symptoms, which makes the symptomatology unespecified and may delay the diagnosis 
and the therapeutic intervention. Complications secondary to HCM can also be 
responsible of the clinical symptoms and signs which can make a patient stop being 
asymptomatic and beginning to develop clinical manifestations. Those complications are 
specially related to arrythmias and heart failure symptoms (Figure 4). 4, 8, 11, 18, 20 
Sudden cardiac death is mainly developed due to ventricular arrythmias, as non-
sustained ventricular tachycardia is suffered by 20-30% of HCM patients and they 
suppose a major risk factor for sudden cardiac death. The process responsible of 
arrythmias in HCM is not properly known yet; it may be implied the ventricular 
remodeling due to cardiac hypertrophy and fibrosis and myocardial ischemia and 
disarray. 2, 20 
Figure 4. Schematic summarizing the main HCM symptoms, complications and management. Took from Jacoby 
D, DePasquale E, McKenna W. 2013. «Hypertrophic cardiomyopathy: Diagnosis, risk stratification and treatment.» 
Canadian Medical Association Journal 127-134 
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People with HCM use to complain of exertional dyspnea or fatigue which may be 
induced by diastolic dysfunction and LVOTO, which is also associated to worse 
prognosis. Mitral regurgitation can be responsible of dyspnea too. Systolic function is 
usually preserved until final steps of the disease, so it is not so strongly related to 
dyspnea as the other parameters until HCM is really developed. LVOTO can be suspected 
due to a systolic ejection murmur which is best heard in the between the apex and the 
left sternal border of increasing intensity with decreasing preload maneuvers. 10, 18, 20 
Chest pain is a common symptom which takes place in HCM patients, most of the time 
due to injured coronary microvascular function caused by altered intramural vessels 
which induce an inadequate vasodilation. It could have typical features of angina or not. 
The chest pain can be limiting and supposes a challenge in order to differentiate it only 
through clinical data from classical obstructive atherosclerotic coronary disease. LVOTO 
can also be implied in chest pain.2, 14, 20 
Palpitations suppose another HCM symptom, which can be caused by cardiac 
contractions or ventricular ectopy, and even due to non-sustained ventricular 
tachycardia. However, if palpitations episode is longer than a few minutes, atrial 
fibrillation and ventricular arrhythmia should be suspected, although other 
supraventricular arrhythmia could be the responsible, which also manifest with other 
unspecific symptoms such dyspnea, especially in case of atrial fibrillation and even, as 
has been said before, can provoke presyncope and syncope. Nevertheless, the risk 
entailed by atrial fibrillation and ventricular arrhythmia compels to exclude them by ECG 
monitoring, even with an implantable loop recorder if necessary. 10, 18, 20 
Syncope or pre-syncope can be suffered by patients with HCM due to LVOTO, as they 
can also be induced by hypovolaemia, complete heart block, sinus node dysfunction, 
ventricular tachycardia or abnormal vascular reflexes. 20 
Heart failure symptoms are frequent, but the clinical profile is so different among 
patients, as some of them can develop a systolic left ventricular dysfunction or left 
ventricular outflow tract obstruction. In other patients, diastolic dysfunction without 
reduced ejection fraction will be found. 4, 8, 18, 20 
It is important to remark the fact that atrial fibrillation and other supraventricular 
arrhythmias could exacerbate heart failure symptoms. In the majority of HCM patients, 
their myocardium develops during all their lives a progressive myocardial fibrosis and 
wall thinning remodeling process, which results in creeping diminished LV diastolic and 
systolic function, often accompanied by mild or moderate LV dilation and progressive 
decreased LV thickness, finally resulting in the decreasing ejection function, knowing this 
phase as the burn out or the hypokinetic-dilated phase. However, the outcome can be 
starring by LV diastolic dysfunction, sometimes associated to atrial dilation with absence 
or just little LV dilation. The mitral regurgitation can result in pulmonary hypertension in 
advanced stages. 10, 18, 20 
As has been said the chronic heart failure symptoms in HCM are similar indistinguishable 
from other heart failure causes, and acute heart failure precipitators are the same as 
general population, between the most remarkable atrial fibrillation, supraventricular 
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tachycardia, sustained ventricular tachycardia, acute mitral regurgitation due to acute 
chordal rupture or an infective endocarditis, myocardial ischemic attack and other 
comorbidity such anemia, hyperthyroidism and pregnancy. 20 
1.3 IMAGING HCM 
The main imaging test when addressing a patient with hypertrophy will be 
echocardiography, although the suspicion may have been given by electrocardiographic 
patterns of left ventricular hypertrophy. Echocardiography is supported by other 
imaging tests such as Gadolinium-based contrast cardiac magnetic resonance (CMR) or 
computed tomography (CT) that also help rule out other possible etiologies that produce 
secondary ventricular hypertrophy. Once these possibilities have been ruled out and 
there is evidence of ventricular hypertrophy (more than 15 mm of ventricular wall), a 
genetic test will be carried out. 10, 14, 17, 20 
1.3.1. ECHOCARDIOGRAPHY  
Echocardiography is the main image testing when diagnosing and monitoring HCM; 
maximum diastolic wall thickness should be measured using at least 2D short axis views 
in all LV segments, including base and apex (Figure 5), which should also include LV 
evaluation function, pulsed Doppler of mitral valve inflow, tissue Doppler velocities at 
the mitral annulus, pulmonary vein flow velocities, pulmonary artery systolic pressure 
and the LA size and volume. The most appropriate moment to measure the LV wall is 
the end-diastole, especially when studying short-axis views.20  
 
Most important parameter when performing an echocardiography due to HCM 
suspicion is the LV wall thickness and its level. Once hypertrophy is detected, it is 
essential to examine all the segments from base to apex. Usually the most affected 
Figure 5. Asymmetric hypertrophy of the interventricular septum (A) and concentric (B) and apical (C) LV 
hypertrophy. Took from Makavos G, Kairis C, Tselegkidi ME, Karamitsos T, Rigopoulos AG, Noutsias M, Ikonomidis 
I. «Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis and treatment.» Heart Failure 
Reviews (2019) 
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myocardial segment basal interventricular septum but can be extended to other 
locations such lateral wall and posterior septum; apex and the right ventricle can also 
be affected, so parasternal and several apical views should be performed to diagnose 
apical HCM.  The diagnose can be a challenging work when HCM is limited to one or two 
segments, especially if they are located in sites which being studied by echocardiography 
entails a difficult work.18, 20  
The extension and the severity of the myocardial hypertrophy should be evaluated 
according to a standardized protocol using several echocardiography projections, which 
respects correct orientation and beam alignment along orthogonal planes in order to 
avoid false positives results due to overestimation of the wall thickness when oblique 
segments are studied (Figure 6). 18, 20 
Echocardiography also is an important tool identifying LVOTO, which an important 
parameter in order to manage symptoms and making the sudden cardiac death risk 
stratification. LVOTO must be studied by 2D and Doppler echocardiography at rest and 
during a Valsalva maneuver, both with the patient sitting and then in semi-supine 
position. 11, 18, 20 
Figure 6. Comparison of normal myocardium, BSH, HCM, and concentric LVH on conventional two-dimensional 
echocardiography. PLAX = parasternal long axis view, SAX = short axis view, A4CH = apical 4-chamber view, A3CH= 
apical 3-chamber view. Took from Kelshiker M, Mayet J, Unsworth B, Okonko D. 2013 «Basal Septal Hypetrophy.» 
Current Cardiology Reviews 
 13 
If there were no gradient measured after trying in those two positions, it would be 
recommended to trying it again on stand position. If the three positions fail in provoking 
LVOTO>50 mmHg, stress echocardiography should be performed but only in 
symptomatic patients, as in asymptomatic patients exercise provocation has not been 
properly evaluated, and the decision will be according to particular patients whose 
lifestyle and treatment depend on the presence of LVOTO gradient. Nevertheless, 
dobutamine echocardiography is not recommended since it could be poorly tolerated 
by the patient. Every patient whereas symptomatic or not must be studied in order to 
evaluate LVOTO gradient, as it is used to make the prognosis according to the sudden 
death risk. 20 
The next step in evaluating HCM by echocardiography should be the diastolic function 
by Doppler echocardiography as their sensitivity in measure the diastolic function is high 
although there is any diagnostic hallmark of disfunction (Figure 7). Loading conditions, 
heart rate and the patient age must be taken into account when studying the diastolic 
dysfunction as they are factors which can alter the test conclusions. In order to be 
complete and valuable, the study should include Doppler myocardial imaging, 
pulmonary vein flow velocities, pulmonary artery systolic pressure and LA size as part of 
the routine evaluation of a HCM patient. If the LV shows a restrictive filling pattern, 
which is defined by mitral peak velocity of early filling (E) and mitral peak velocity of late 
filling (A) ratio is at least bigger than 2, that patient would have a worse outcome without 
the ejection fraction having no role in that conclusion. 11,20 
Although systolic contractile LV function is typically normal or increased in patients with 
HCM until very advanced remodeling phases, it should be studied by echocardiography, 
Figure 7. (A) Mitral inflow showing restrictive inflow pattern with elevated E/A ratio. (B) Four chamber view showing 
LA enlargement. (C) Tricuspid regurgitant jet velocity and right atrial pressure to estimate the higher pulmonary 
artery pressure. (D) Lateral annular tissue Doppler (TD) velocities, e´ reduced and impaired LV relaxation. (E) 
pulmonary venous flow velocity showing high left atrial pressures through blunted systolic atrial flow -S- and 
increased atrial velocitiy -A-. Took from Maron MS, Rowin EJ, Barry MJ. 2017. «How to image hypertrophic 
cardiomyopathy.» Circulation: Cardiovascular Imaging 1-15. 
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but through myocardial longitudinal velocities and the strain and strain rate with 
Doppler myocardial imaging or speckle tracking techniques (Figure 8) inasmuch as the 
ejection fraction is poor measure in presence of myocardial hypertrophy. It is possible 
the ejection fraction to be normal, but the other parameters mentioned to be reduced, 
even before there is an observable wall thickening. The myocardial longitudinal 
deformation is usually reduced in the locations where observable hypertrophy is 
remarkable, as the longitudinal strain has become recently as the most promising 
parameter when evaluating the systolic function in HCM, since it can demonstrate 
subclinical LV systolic dysfunction due to impaired myocardial contraction even with 
preserved ejection fraction.  14, 20 
In conclusion, echocardiography is one of the first test which can help to approach a 
suspected HCM case. Furthermore, it can be useful to differentiate between HCM and 
other diseases responsible of LV hypertrophy, such phenocopies as Fabry disease. 
Information obtained like sparkling or granular myocardial tissue, soft pericardial 
effusion, interatrial septum or aortic valve thickening with ejection fraction reduction 
due to a restrictive pattern, it is highly suggestive of storage or infiltration heart disease. 
13,18, 20 
Finally, transesophageal echocardiography is used to be performed when patient´s 
echocardiographic windows are considered poor, as it must also be performed before a 
surgical treatment as septal myectomy, both during the process and after in order to 
search for possible complications such ventricular septal defect, aortic regurgitation and 
residual LVOTO. 20 
If studying properly some segment is not possible with echocardiography, ultrasound 
contrast agents or a CMR should be performed. 20 
The 2014 ESC Guidelines recommendations for echocardiography in HCM patients are 
collected in Table 1. 
Figure 8. Hypertrophic cardiomyopathy with asymmetric hypertrophy of the interventricular septum (a) and 
impaired longitudinal strain − 16.4% particularly in the basal and midseptum segments (b). Obtained from 
Makavos G, Kairis C, Tselegkidi ME, Karamitsos T, Rigopoulos AG, Noutsias M, Ikonomidis I. «Hypertrophic 
cardiomyopathy: an updated review on diagnosis, prognosis and treatment.» Heart Failure Reviews (2019). 
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1.3.2. CARDIAC MAGNETIC RESONANCE 
Cardiac magnetic resonance (CMR) has become a very important routine resource in 
order to diagnose HCM (Figure 9), specially during this last decade, as it is helpful in 
diagnosing HCM in patients with poor acoustic windows for echocardiography and to 
make easier the visualization of some regions difficult to evaluate in other image test, 
such anterolateral left ventricle wall, the apex or the right ventricle.  Despite the fact 
CMR is difficult to analyze, particularly when approaching a very heterogeneous disease 
as HCM, it is a fundamental step of the clinical diagnoses or suspicion of HCM. 8, 13, 14, 18, 
20 
CMR is superior to TTE in the measurement of LV mass, but it is weakly correlated to 
maximum wall thickness, being normal in some HCM patients. 20 
CMR provides accurate measurements of maximal LV wall thickness and detection of 
apical aneurysms, thrombi, or myocardial crypts, which may represent a subtle feature 
of HCM in sarcomeric gene mutation-positive patient. (Figure 10). Other heart structures 
must be also studied, such the left atrial and the papillary muscles and trabeculations of 
the left ventricle wall. The sensitive of CMR is bigger than TTE in diagnosing papillary 
muscle abnormalities in patients with HCM. Both left and right ventricle ejection 
percentage should be also measured. 8, 13, 14, 18,  
2014 ESC GUIDELINES RECOMMENDATIONS FOR TRANSTHORACIC ECHOCARDIOGRAPHY 
IN HCM PATIENTS 
EVIDENCE CLASS 
AND LEVEL 
Initial evaluation in HCM patients: transthoracic 2D and Doppler echocardiography, both in 
rest a during the Valsalva maneuver and in sitting and semi-supine positions. Standing 
position echocardiography will be performed if any gradient has been provoked with the 
previous trials 
Class I Level B 
In order to provoke LVOTO through changing sitting, standing and semi supine position and 
mitral regurgitation induced by exercise, 2D and Doppler echocardiography should be 
performed in every symptomatic patient with resting or provoked instantaneous LVOTO <50 
mmHg 
Class I Level B 
When a patient is going to be undergone to a septal alcohol ablation, a intracoronary 
contrast echocardiography is recommended in order to be sure of localization of alcohol Class I Level B 
Transthoracic 2D echocardiography is recommended to measure the maximum wall 
thickness during diastole in short axis views and in all segments from base to apex Class I Level C 
Pulsed Doppler of mitral valve inflow, tissue Doppler velocities at the mitral annulus the 
pulmonary vein flow velocities, pulmonary artery systolic pressure and the measure of LA 
volume with the aim of evaluating the LA enlargement is also recommended to be 
performed in all patients 
Class I Level C 
In case of suspicion of LV apical hypertrophy or aneurism, transthoracic echocardiography 
using intravenous contrast agents should be considered as CMR imaging alternative Class IIa Level C 
Patients without any symptoms but with a resting or provoked LVOTO <50 mmHg may be 
undergone a 2D and Doppler echocardiography in the three mentioned positions if the 
presence or absence of relevant LVOTO would condition the lifestyle patient´s decisions or 
treatment 
Class IIb Level C 
Table 1.  Chart summarizing the 2014 ESC Guidelines recommendations in Echocardiography for HCM patients. 
Modified from Task A, Elliot P, Uk C et al. «2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy.» European Heart Journal (2014): 2733-2779. 
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Late gadolinium enhancement (LGE) determines the presence and extent of myocardial 
fibrosis. The extent and the distribution of LGE which give more information about the 
risk of a certain patient, as it should be measured according to the percentage of the 
total left ventricle mass the enhancement occupies, since LGE is considered a modulator 
factor when assessing sudden cardiac death. That quantification has been developed in 
order to a standardized core laboratory study design, which make the measurement 
results reproducible. However, different in CMR hardware and diverse LGE protocols can 
make this protocol difficult to enforce in al centers, so qualitative estimation of the 
percentage of LGE by visual interpretation of an expert can be useful in the most cases. 
14, 18, 20 
 
LGE is present in about 65% of HCM patients; the typical pattern distribution are mid-
Figure 10. CMR in apical HCM. (A) End-diastolic frame of the four-chamber cine showing the apical hypertrophy. (B) 
End-systolic frame of the four- chamber cine showing the obliteration of the cavity at the apex and the apical 
displacement of papillary muscles. (C) Late gadolinium enhancement image at the four-chamber view. Obtained 
from Makavos G, Kairis C, Tselegkidi ME, Karamitsos T, Rigopoulos AG, Noutsias M, Ikonomidis I. «Hypertrophic 
cardiomyopathy: an updated review on diagnosis, prognosis and treatment.» Heart Failure Reviews (2019) 
 
 
Figure 9. Clinical utility of CMR. CMR= cardiac magnetic resonance; LVH= left ventricle hypertrophy;  SCD= sudden 
cardiac death; LGE: late Gadolinium enhancement; HCM= Hypertrophic Cardiomyopathy. Modified from Geske 
JB, Ommen SR, Gersh BJ,. «Hyperthropic Cardiomyopathy. Clinical Update .» Heart Failure (2018): 364-375 
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wall hypertrophy areas and the anterior and posterior right ventricle insertion points. It 
could be said until HCM very advanced stages, when all the LV wall is thin and the LGE 
is distributed all around the wall thickness, LGE is not usual to be found in non-
hypertrophied locations. Certain delay in the washout of the Gadolinium contrast is 
highly suggestive of space expansion, which can be caused by myocyte loss fibrosis or 
an infiltrative process. LGE quantification is based on an operator-defined threshold of 
signal intensity, which usually is from 2 to 6 standard deviations above normal 
myocardium. Other LGE quantification accepted are the assumption of full width at half 
maximal signal (FWHM) which is defined as pixels that are ≥50% the signal intensity of a 
hyperenhanced area or entail manual delineation of ‘regions of interest’ have also 
demonstrated high reproducibility. 14, 18, 20 
Furthermore, the LGE also have some paramagnetic properties, which show a 
shortening T1 relaxation times in the myocardial affected region, as LGE provides a 
myocardial dichotomization into bright (enhanced) versus dark (nulled), corresponding 
respectively to affected myocardium and normal tissue. 13,16 In this way, T1 imaging 
before Gadolinium contrast administration is a useful tool in order to make an 
estimation of myocardial volume of contrast distribution which is shown in extracellular 
volume fraction. Therefore, evaluation of focal and diffuse fibrosis using both LGE and 
T1 mapping techniques are useful tools in prognosing HCM. 14 
The CMR utility is related to the possible association with higher incidence of myocardial 
stiffness and adverse LV remodeling, which includes the wall thinning, the end-systolic 
dimension and it is also related to increased risk of abnormalities in regional wall 
movement. All those events evolve in increasing heart failure with NYHA functional 
2014 ESC GUIDELINES RECOMMENDATIONS FOR CMR IN HCM PATIENTS EVIDENCE CLASS AND LEVEL 
In patients with poor echocardiographic windows CMR with LGE will be performed if 
there is HCM suspicion in order to confirm the diagnosis. There must be no 
contraindications 
Class I Level B 
CMR should always be performed and assessed by experienced teams in CMR and heart 
muscle diseases Class I Level C 
Patients fulfilling diagnostic crtieria for HCM should be considered to undergo a CMR with 
LGE to evaluate anatomy, ventricular function and myocardial fibrosis presence and 
extension. There must be no contraindications 
Class IIa Level B 
If there is suspicion of apical hypertrophy or aneurysm, CMR with LGE should be 
performed Class IIa Level C 
If cardiac amyloidosis is suspected, CMR with LGE should be performed Class IIa Level C 
Before performing septal alcohol ablation or myectomy, to evaluate the extent and 
distribution of hypertrophy and myocardial fibrosis Class IIb Level C 
Table 2. Chart summarizing the 2014 ESC Guidelines recommendations in CMR for HCM patients. Modified from 
Task A, Elliot P, Uk C et al. «2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy.» 
European Heart Journal (2014): 2733-2779. 
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classes III-IV and its consequences, as hospitalization, morbidity and all- cause heart 
failure related mortality. 20 
In absence of contraindications, ESC Guidelines recommend all patients with diagnosed 
or suspected HCM to be undergone a CMR with LGE as long as there are experienced 
teams in cardiac imaging and evaluating heart muscle disease as it is highly necessary 
the correct CMR interpretation (Table 2). 20 
CMR magnetic properties in isolation are useful to distinguish the different HCM 
phenocopies, since the distribution and severity of the Gadolinium contrast interstitial 
expansion can suggest a specific disease. In this way, Fabry´s disease typical CMR shows 
a reduced T1 signal without contrast at the same time there is presence of anterolateral 
LGE. Cardiac amyloidosis pattern are variable, as the global, subendocardial or 
segmental LGE, but a highly specific pattern consists of myocardial and blood-pool 
Gadolinium kinetics caused by myocardial and blood T1 signals. 14, 20  
It is important to remark in every patient who is suspected of cardiac amyloidosis should 
be undergone a CMR. Likewise, not only the distribution of gadolinium can help to make 
a suggestive diagnose different from HCM, but also the absence of fibrosis may be useful 
in order to differentiate HCM from physiological adaptation LV hypertrophy in athletes. 
However, it must be taken into account the fact that LGE can be absent in some HCM 
patients, especially in those who are young patient and have a mild disease. Comparison 
between CMR and echocardiography is shown in Figure 11. 14, 20 
Figure 11. Cardiovascular magnetic resonance (CMR) and 2-dimensional echocardiography (2DE) imaging HCM. 
Took from Maron MS, Rowin EJ, Barry MJ. 2017. «How to image hypertrophic cardiomyopathy.» Circulation: 
Cardiovascular Imaging 1-15. 
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CMR is also useful when preparing the surgical planning for septal alcohol ablation or 
myectomy, especially in patients with multilevel LV obstruction, for example, both 
LVOTO and mid cavity HCM, or patients with RV outflow tract affected. Once the surgical 
procedure has been carried out, CMR offers information about the amount of tissue 
necrosis caused by the ablation as well as the regression of LV mass and the scarring 
location. 20 
CMR is also useful when preparing the surgical planning for septal alcohol ablation or 
myectomy, especially in patients with multilevel LV obstruction, for example, both 
LVOTO and mid cavity HCM, or patients with RV outflow tract affected. Once the surgical 
procedure has been carried out, CMR offers information about the amount of tissue 
necrosis caused by the ablation as well as the regression of LV mass and the scarring 
location. 20 
1.4. PROGNOSIS OF HCM  
The next step after the confirmatory diagnosis of HCM is to make an approach of the 
sudden death risk as part of the routine evaluation. ACC/AHA guidelines recommend 
evaluating all HCM patients in order to identify the highly risk cases through non-
invasive data presence. 13,18The main factors to take into account to approach the 
sudden cardiac death risk are age of the patient at first evaluation, the left ventricle 
hypertrophy, the left atrial enlargement, the presence and severity of LVOTO, the family 
background of sudden cardiac death, personal history of non-sustained ventricular 
tachycardia and previous episodes of unexplained syncope (Figure 12). 6, 18  
Figure 12. Risk Stratification and Primary Prevention of Sudden Death with Implantable Cardioverter–Defibrillators 
(ICDs) in Patients with HCM. Obtained from Maron BJ. « Clinical Course and Management of Hypertrophic 
Cardiomyopathy.»  The New England Journal of Medicine (2018): 655-668 
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LV massive hypertrophy (about ≥30 mm) without any other risk factor, which carries 
more risk than is acceptable, so primary prevention with a prevention implantable 
cardioverter defibrillator therapy, should be offered to the patient. Altogether, it seems 
to be a linear correlation between wall thickness and sudden death risk in HCM, 
especially when talking about 30 mm measurements. Given these points, it is easy to 
understand the importance of correct wall thickness measurement, so any doubt should 
be stablished when considering CMR in the initial evaluation complementing 
echocardiography, particularly when hypertrophy is located in inaccessible with 
echocardiography. 14, 18  
Although the European Society of Cardiology supports a risk stratification novel score 
which incorporates clinical variables (Figure 13), even those not included in ACC/AHA 
guidelines, as the evaluation of the LVOTO, the US/Canadian guidelines sustain LVOTO 
as an independent risk factor entails high difficulty to read into given the dynamic nature 
of gradients and the fact they can be treated. All in all, LVOTO is an important risk factor 
so it must be taking into account to score the patient´s sudden death risk.13 In order to 
determine the absence of LVOTO and categorizing definitely the patient as non-
obstructed, changing his prognosis related to adverse events and sudden death risk, 
exercise echocardiography may be useful. For the most part of asymptomatic patients 
without LVOTO, the likelihood of future development of limiting and progressive heart 
failure symptoms is low. What is more, most part of nonobstructive HCM patients will 
never need medical therapy, as drug treatment in symptomatic patients would just be 
limited to atrial-ventricle node blockers, improving myocardial blood flow and LV filling 
time. Into the small percent of the nonobstructive patients who will develop long-term 
symptoms, mostly related to diastolic dysfunction, the only definite treatment option 
will be heart transplant, like every advance diastolic heart failure patient. 14 
Figure 13. HCM risk sudden cardiac death calculator.  SCD= sudden cardiac death; LV=left ventricle; LVOT= left 
ventricle outflow tract; VT= ventricular tachycardia Took from www.escardio.org 
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A relationship between LGE and long-term adverse events has been evaluated in several 
studies, but all of them are limited by incomplete risk assessment and differences in in 
scanning procedures and the absence of a protocol for LGE quantification. The analyzed 
data show there is an association between LGE and mortality due to cardiovascular 
issues, heart failure and all-cause death, although the increased risk of sudden cardiac 
death is not that high. However, when the distribution of LGE is extensive, about ≥15% 
of LV mass may identify HCM patients at increased risk for sudden death. Those patients 
would be benefited from primary prevention therapy. What is more, it seems the 
extension of LGE on CMR is consistently related to episodes of non-sustained ventricular 
tachyarrhythmia, but this evidence is less strong. However, non-sustained ventricular 
arrythmias are an independent risk factor taking into account at the time of evaluating 
the sudden cardiac death risk, not because of the demonstrated relation but due to the 
risk that arrythmia in isolation carries in any patient situation. Currently, LGE is not an 
independent predictor of sudden cardiac death, probably due to the recent 
incorporation of the CMR in the routine evaluation in HCM patients and the differences 
in follow-up duration and the differences when evaluating the quantity of LGE.14,18, 20 , 
Left atrial size measurement, although itself is not a direct parameter to make decisions 
in sudden death prevention, as it has not been demonstrated its independent 
relationship between the left atrial enlargement and the sudden death risk. However, 
the LA enlargement has been proved as a marker for heart failure death or atrial 
fibrillation; the measures from which the risk is consider are >48 mm in transverse linear 
dimension or ≥118 mL as chamber volume. 14, 20 
It is remarkable the importance of the HCM phenotypic subgroup of LV apical aneurysm 
formation, which sometimes is related to mid-cavity hypertrophy and LVOTO, which is 
not included in the traditional risk stratification algorithm, although aneurysms must be 
considered as a high risk profile owing to the more likeliness of adverse events related 
to the disease such thromboembolism apart from sudden death. Due to the possible 
echocardiography limitations in studying some patient´s LV chamber, CMR or contrast 
echocardiography if CMR is not available should be performed when there is suspicion 
of apical aneurysm or potential apical thrombus. 14, 20 
Not only sudden cardiac death is taken into account when talking about HCM prognosis, 
but progressive heart failure symptoms are also one of the most relevant issues when 
evaluating and studying the patient´s profile and long-term evolution.   
Diastolic dysfunction has been studied by noninvasive test as a measure for intracardiac 
filling pressures. Regardless, the reality is there is any echocardiographic parameter 
considered as a reliable measure of filling pressures. In other words, diastolic function 
in HCM is very complex as it is the result of several facts including LV hypertrophy, 
abnormal myocardial blow flow at microvascular level, myocardial fibrosis and abnormal 
calcium handling. Together with this idea, it is explained why only a mild association 
between transmitral Doppler measures of mitral inflow (E/A) or tissue Doppler imaging 
from mitral annular velocities with simultaneous LA pressure measurement has been 
demonstrated. Furthermore, no relation has been showed between Doppler measures 
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of diastolic function at rest and then with exercise duration to predict future risk of 
progressive heart failure. 14 
Notwithstanding, HCM cases with restrictive mitral inflow patterns are an exception, as 
those correlations have been proved. Altogether, in every patient along with his profile, 
must be measured by echocardiography the filling pressures, which left atrial size, mitral 
deceleration time, estimated pulmonary artery pressures, pulmonary venous inflow, 
transmitral velocities and tissue Doppler. 14 
Figure 14 summarizes schematically the role of clinical manifestations and imaging in 
HCM prognosis in order to make a therapeutic approach. 
Overall, systolic function in HCM patients is normal or even supernormal respecting the 
ejection fraction. As shown before in its corresponding section, the longitudinal strain is 
the most promising parameter when studying the systolic function HCM. That marker 
can indicate the subclinical LV dysfunction despite the ejection fraction is totally normal. 
Nevertheless, the prognostic correlation is unclear. In some studies, it has been shown 
the fact that about 10% of the nonobstructive patients develop end-stage HCM phase, 
which includes an ejection fraction under 50% by echocardiography or CMR; and those 
studies also show that percent has an increasing tendency. The only clinical markers 
whose correlation to end-stage HCM has been proved are the family history of end-stage 
Figure 14. Flow diagram outlining the role of imaging in hypertrophic cardiomyopathy (HCM) management 
strategies. HCM= hypertrophic cardiomyopathy CMR= Cardiac Magnetic Resonance; Echo= echocardiography; LV= 
left ventricle; LGE= late Gadolinium enhancement LVH= left ventricle hypertrophy; ICD= implantable cardiac 
defibrillator; LVOTO= left ventricle outflow tract obstruction; PM= papillary muscles; MV=mitral valve.  Modified 
from Maron MS, Rowin EJ, Barry MJ. 2017. «How to image hypertrophic cardiomyopathy.» Circulation: 
Cardiovascular Imaging 1-15. 
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HCM and LGE ≥20%. End-stage HCM is also associated with higher likelihood of 
ventricular tachycardia or fibrillation and advanced heart failure symptoms, all of them 
supposing an important life-threatening event. Early diagnose of systolic dysfunction 
may allow to manage it with medical treatment and primary preventive ICD therapy. 14, 
18, 20 
1.5. DIAGNOSTIC ALGORITHM 
Diagnostic algorithm is represented in Figure 15. HCM diagnosis is based on the 
identification of increased LV wall thickness (more than 15mm or more than 3 standard 
deviations from predicted) which can be demonstrated by several image modalities, 
such echocardiography, cardiac MRI or cardiac CT. Although more than one cause can 
be responsible of increased wall thickness at the same time as HCM, such hypertensive 
cardiomyopathy, the suspicion must take place when the LV hypertrophy is more 
intense than expected for severity and time of evolution of the hypertension. 11, 20 
Characteristic HCM MRI shows LGE with evidence of scar tissue. However, the absence 
of the LGE  does not discard the disease. Besides, HCM includes other traits as changes 
in the valvular apparatus or in the myocardial morphology or architecture, since the 
presence of myocardial fibrosis is not uncommon at the HCM diagnosis or during its 
evolution. 14,18, 20 
Sometimes HCM can be suspected by abnormalities in ECG, which must be performed 
in every patient with suggestive HCM symptoms or signs, although there is not a specific 
pattern related to HCM which can be considered pathognomonic. Every patient who 
shows unexplained symptoms or abnormalities in ECG or has family background of 
premature cardiac disease should be considered to discard HCM. 11,18,20 
Figure 15. Schematic summarizing the general approach to the diagnosis of HCM. Took from 2014 ESC Guidelines 
on diagnosis and management of hypertrophic cardiomyopathy (European Heart Journal, 2014) 
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Genetic test has incredibly changed the way of diagnosing HCM. The development of 
next-generation sequencing (NGS) allows to study thousands of genes and that is why 
all the guides include genetic test with the highest recommendation levels in order to 
diagnose HCM. Not only are they useful in identifying a pathogenic mutation responsible 
of HCM but also they have direct application in offering reproductive counselling and 
the follow-up of the first-degree familiars of a person with HCM.  1,2,3,4, 17, 20 
In summary, every patient whose symptoms or signs make us suspect of HCM will be 
undergone a cardiac imaging. Actually, echochardiography and cardiac MRI with 
Gadolinium are the two tests usually performed, and as it has been said before, an ECG 
will be also performed. Other tests could be made, but it is a clinical and individualized 
decision. Once specific syndromes mentioned before are discarded, it is time to study 
the likelihood of a mutation is responsible of the disease, and the prognosis of the 
patient and his family.  In other words, a genetic test should be considered with the aim 
of identifying the mutation responsible of HCM. This order when proceeding with the 
diagnostic algorithm is more appropriate when it comes to a proband case. 1, 17, 18, 2 
1.6. GENETIC DIAGNOSE  
When a patient is clinically diagnosed with HCM, it is important to take into account not 
only the familiar background, which must be investigated since the first suspicion of 
HCM, but also study the risk of the family members. 4 
Depending on the mutation implicated in each case, it would be necessary to make a 
screening of the first-degree relatives. 10 It is highly recommended to make a detailed 
family tree composed by at least 3 generations as part of the first evaluation made when 
HCM is suspected in a proband patient (Figure 16). They must include family 
background, geographic origin and symptoms related to heart diseases or sudden death 
(including unknown death cause and neonatal sudden infant death syndrome). It is 
considered to be the proband case the first patient studied in the family, and he can be 
dead or alive. The possibility of consanguinity must also be discarded.4 
Figure 16. A genealogical tree showing autosomal inheritance in HCM. Circles represent women, rectangle men. 
Blue figures are patients affected from HCM, The arrow points the proband patient, as it is the first studied in the 
family; strikethrough circle means dead person. Modified from Barriales R, Gimeno J, Zorio E. «Protocolo de 
actuación en las cardiopatías familiares: síntesis de recomendaciones y algoritmos de actuación.» Revista 
Española de Cardiología (2016): 300-309  
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Monogenic diseases, such HCM, are caused by mutations or rare variants in some genes; 
most of the polymorphism are not pathogenic, but in some cases can act like modulating 
or modifier factors. As it has been said before, almost always HCM has been considered 
mainly an autosomal dominant disease, with a 50% risk of transmission to offspring. Old 
people and patients with non-classical features have lower likelihood of finding a 
mutation responsible of the HCM than people whose family is affected by the  disease. 
4,20  Once a pathogenic or likely pathogenic mutation is identified in the proband case, it 
is possible to confirm the HCM diagnosis and make a prognosis of the disease (Figure 
17).  
It would be recommended their relatives to be genetically tested, and if the result is 
positive (they carry the same mutation), they should be clinically evaluated; this 
combination is the best method to identified high and medium risk individuals and 
discharge a great number of non-carrier relatives. The genetic testing allows the 
screening of the patient´s relatives which facilitates the early diagnosis in pre-
symptomatic phases and giving clinical follow-up and reproductive advice. The 
identification of a benign variant, usually a polymorphism in the proband case is not 
useful for the diagnosis or the relatives´ study, unless their function as modulating or 
modifiers factors is demonstrated in the presence of certain environmental factors. 4, 20 
The main recommendations about genetic testing in HCM by ESC 2014 guidelines are 
shown in Table 3.  
Figure 17. Schematic summarising the genetic procedure. Took from 2014 ESC Guidelines on diagnosis and 
management of hypertrophic cardiomyopathy (European Heart Journal, 2014) 
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Otherwise, variants of unknown significance (VUS), which are changes in the nucleotide 
sequence without current knowledge about its pathogenicity and are useless in 
supporting the diagnosis or stablishing the familiar disease risk. European Cardiology 
Society has recently recommended keeping up VUS porters, just in case the 
pathogenicity of the variant is discovered in the future, changing the patient´s 
prognosis.4 
Despite genetic study is negative, what is, there has not been found any pathogenic or 
likely pathogenic mutation because there is no suspicious variant in the study, HCM and 
its familiar transmission must not be discarded if the patient has clinical diagnosis of the 
disease, as it is not known all the mutations and genes implicated in HCM, so we must 
consider that family affected by HCM. If the genetic testing is negative in relatives and 
they do not have developed any clinical sign or symptom suggesting HCM, they do not 
have to be followed-up, but must re-assest if they manifest any symptom or sign 
suggesting cardiac problems, or if new familiar information is revealed.4,7, 20 
It is important to remark from an ethic point of view the  results of studies which 
evidence there is not a relevant psychological adverse effect related to the clinical and 
genetic screening both in children and adults with risk of HCM, as long as they are 
managed in centers with professional physicians dedicated to Familiar Cardiopathies. 20 
2. HCM GENETICS  
As previously mentioned, HCM-causing mutations are detected in about 60% of HCM 
probands, and they are characterized by locus and allelic heterogeneity; it is remarkable 
the fact that novel individual mutations are highly frequent. 1, 6, 7 
Before talking about specific HCM mutations, it is important to make a brief summary 
about the performance of the sarcomere to understand the level the most prevalent 
HCM mutations take place.  
2014 ESC GUIDELINES RECOMMENDATIONS FOR GENETIC TESTING IN HCM PATIENTS Evidence Class and Level 
Patients with diagnostic criteria of HCM, when its result allows to screen the rest of the 
family Class I Level B 
The genetic test must be carried out in certified laboratories with expertise in the 
interpretation of cardiomyopathy-related mutations 
 
Class I Level C 
Patients with clinical signs or symptoms which suggest HCM, as the genetic test would 
confirm the diagnosis Class I Level B 
Patients with borderline diagnosis of HCM, described as left ventricular wall thickness 12-
13mm or hypertrophy in the presence of hypertension, athletic patient of valve diseases, 
once the patient has been studied by specialist teams 
Class IIa  Level C 
In order to make a screening on relatives, it would be recommended to make a post-
mortem genetic testing in stored tissue of deceased patients with confirmed HCM Class IIa Level C 
Table 3.  Chart summarising the 2014 ESC Guidelines recommendations in CMR for HCM patients. Modified from 
Task A, Elliot P, Uk C et al. «2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy.» 
European Heart Journal (2014): 2733-2779. 
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The cardiomyocyte basic motor unit is the sarcomere, which its fundamental structure 
are the thick and the thin filaments (Figure 18). The thick filament is basically composed 
by about 300 myosin molecules; each molecule is made up of 2 protein units of beta or 
alpha-myosin heavy chain and 4 myosin light chain molecules. The thin filament 
structure is a repetition of actin molecules which are closely related to the regulatory 
troponin complex, whose components are troponin T (TnT), troponin I (TnI) and troponin 
C (TnC)) and α-tropomyosin. The interaction between actin and myosin is performed by 
de cardiac myosin-binding protein C.1 
Mutations in the genes encoding beta-myosin heavy chain (MYH7) and myosin-binding 
protein C (MYBPC3) account for the 75% of the cases a pathogenic variant is identified 
in a proband. MYH7 mutations are usually found in these four locations: the actin 
binding site, the nucleotide binding pocket, the hinge region adjacent to the binding site 
for two reactive thiols and in the alpha-helix close to the essential light chain interaction 
site. That is why the effect of the mutated protein depends on the mutation position 
too.  5,  20 
The majority of mutations in MYH7 are missense, which means a single nucleotide-base 
substitution results in a non-synonymous single amino acid substitution. On the other 
hand, MYBPC3 mutations use to be nonsense due to insertion or deletion and splicing 
variants or frameshifts causing premature stop codon, inducing a truncated protein 
transcript (truncating type of mutation). 1 
It is believed most missense mutations have a dominant negative effect, which makes 
the mutant protein to be incorporated into the sarcomere disrupting the normal 
sarcomere function and structure, or altering the ligand interaction in the kinase 
domains, or even changing the protein-protein interaction by affecting the surface-
exposed portion. The changes induced in proteins by these mutations can also be related 
to folding process, which can trigger an early degradation. However, it is thought 
haploinsufficiency to be the mechanism responsible of the disease usually in truncating 
mutations. HCM phenotype is suspected to be resulted from a diminished contractile 
function due to altered actin-myosin interactions, and consequent inappropriate 
compensatory hypertrophic remodeling. 1 
Figure 18. The sarcomere. It is composed of bands of highly organized thick and thin myofilaments. Each 
sarcomere is located between 2 Z bands, where titin and thin filaments are anchored. The thick filament fulfills 
motor and regulatory functions thanks to MYH7 and MYBPC3. Image took from Maron BJ. « Clinical Course and 
Management of Hypertrophic Cardiomyopathy.»  The New England Journal of Medicine (2018): 655-668 
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On the other hand, about 10% of the HCM mutations are found in other sarcomere 
genes. These genes are basically related to myosin light chain 2 and 3 (MYL2, MYL3), 
tropomyosin alpha-1 chain (TPM1), cardiac troponin I, C and T (TNNT2, TNNC1, TNNI), 
and Actin Alpha Cardiac Muscle 1 (ACTC1). There are other mutations responsible of 
some cases of HCM, but they are not sarcomeric proteins genes. Less than 1% of the 
mutations are found in Z-disk proteins, such Filamin C (FLNC), Alpha-actinin-2 (ACTN2) 
and Vinculin (VCL). ZASP-LIM binding domain 3 (LBD3) is a Z-Disk protein whose 
mutations can be found in 1-5% HCM cases.  Sarcomere-associated proteins as desmin 
(DES) and Four and a Half Lim Domain Protein-1 (FHL-1) are examples of other proteins 
which can be responsible of HCM development. They can be appreciated in Table 4. 1, 7, 
20 
 Gene Locus Protein Frequency 
Myofilament mutation 
MYBPC3 11p11.2 Cardiac myosin-binding protein C 15-25 
MYH7 14q11.2-q12 ß-Myosin heavy chain 15-25 
TNNI3 19p13.4 Cardiac troponin I <5 
TNNT2 1q32 Cardiac troponin T <5 
TPM1 15q22.1 ß -Tropomyosin <5 
MYL2 12q23-q24.3 
Ventricular regulatory 
myosin light chain <2 
ACTC 15q14 -Cardiac actin <1 
MYH6 14q11.2-q12 α -Myosin heavy chain <1 
MYL3 3p21.2-p21.3 
Ventricular essential 
myosin light chain <1 
TNNC1 3p21.3-p14.3 Cardiac troponin C <1 
TTN 2q24.3 Titin <1 
Z-disc mutation 
LBD3 10q22.2-q23.3 LIM binding domain 3 1-5 
ACTN2 1q42-q43 α -Actinin 2 <1 
ANKRD1 10q23.33 Ankyrin repeat domain 1 <1 
CSRP3 11p15.1 Muscle LIM protein <1 
MYOZ2 4q26-q27 Myozenin 2 <1 
TCAP 17q12-q21.1 Telethonin <1 
VCL 10q22.1-q23 Vinculin/metavinculin <1 
Calcium-handling 
JPH2 20q12 Junctophilin-2 <1 
PLN 6q22.1 Phospholamban <1 
A study developed in Spain among 2014 and 2017 revealed Formin homology 2 domain 
Table 4. Genetic and Molecular Basis of Disease for HCM. Modified from Maron BJ. « Clinical Course and 
Management of Hypertrophic Cardiomyopathy.»  The New England Journal of Medicine (2018): 655-668 
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containing 3 (FHOD3) is a novel disease-causing gene in HCM. Their pathogenic or likely 
pathogenic variants would account for about 2% of HCM cases, similar to the genes just 
mentioned. FHOD3 diaphanous autoregulatory and inhibitory domains interact so the 
protein is in an autoinhibited state, but its location and function are not well known yet, 
so functional studies are required to understand the mechanisms FHOD3 mutation 
carriers develop HCM. 16 
There are other genes whose role in HCM has been considered modifying rather than 
pathogenic, such RYR2, CAV3, and SCN5A. 20 
Actually, it is thought patients with sarcomere protein mutation suffer from earlier 
sudden cardiac death; and more important family background of sudden death is found 
when investigating a proband case with those mutations. It could be related to the fact 
that these patients also use to develop more severe myocardial hypertrophy and fibrosis 
and they are found microvascular disfunctions too. Moreover, patients with several 
sarcomeric proteins mutations, as we can imagine, develop a more aggressive 
phenotype which also shows up earlier in time. However, it is necessary to make more 
studies in order to improve the evidence of this theories. 7, 20 
 
3. METHODS 
In this study, a data base has been made with the genetic test results of the proband 
HCM cases identified in Cantabria between January 2018 and the first week of January 
2020. 291 studies of HCM have undergone a genetic test during those months. 140 
patients were proband cases (48,1%) and the rest (151 cases) were first degree relatives 
who underwent a familial genetic and clinical screening. As the presence of a certain 
mutation is the same in each affected family, in the study we have only taken into 
account proband cases. 
The cases have been diagnosed in the four hospitals in Cantabria (Hospital Marqués de 
Valdecilla, Hospital de Sierrallana, Hospital Tres Mares y Hospital de Laredo), as the 
different Cardiology Departments of those medical center are the responsible of clinical 
HCM diagnose and the doctors who apply for the genetic test.  
The request of genetic test is processed by the Hospital Marqués de Valdecilla Genetics 
Department, and it is sent to an external laboratory located in Galicia (Spain) called 
Health in Code, which sent back the results to Genetic laboratory, who is responsible of 
reporting the Cardiologist the genetic information of the study.  
Health in Code uses two different methods to carry out the genetic test: Next Generation 
Sequencing (NGS) and Sanger Sequencing Method from blood, saliva or tissues, 
previously subjected to extraction and purification processes in order to obtaining 
genomic DNA (QIAsymphony SP, Qiagen). Data sequencing analysis is performed by an 
own bioinformatic pipeline which includes both the demultiplexing sample and all the 
steps necessary to obtain the annotated variants together with their coverage and 
corresponding quality parameters.  
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The genes and capture probes library are Health in Code property. There are two panels 
developed in order to make de genetic diagnose of HCM.  
The first of them is the basic panel which includes 17 genes related to HCM. These 
included genes have been selected according to a clinical criteria and its association to 
a particular phenotype. Two of the genes included in the basic panel (DES and FLNC) are 
related to Noonan Syndrome; PRKAG2 mutations trigger AMP gamma-2 subunit; GLA 
gene is responsible of Anderson-Fabry disease, and LAMP2 causes Dannon syndrome, 
as TTR is the gene related to altered protein which accrues in the amyloidosis heart 
disease. Apart from those genes, there have also been included the most frequent genes 
related to HCM.  
This basic panel allows the Cardiologist to make a confirmatory test of the clinical 
suspicion of HCM with a single test, at the same time as ruling out the specific syndromes 
that we have been mentioning, which clinically could suppose a phenocopy of the 
disease, thus being able to discard these options and confirm others, or vice versa, 
through only one sample. 
The results show those genetic variants which are selected taking into account its 
potential relation to the patient phenotype or important incidental founds. However, it 
must be considered the fact that the variant pathogenicity is not static anymore, as it 
changes over the time depending on the available evidence.  
Sensitivity and specificity when analyzing the punctual substitutions and the small 
insertions or deletions (£ 20 pb) are more than 99%. But despite the higher specificity 
and sensitivity of the test, mistakes can occur in certain situations: already contaminated 
samples at the laboratory arrival, monosomies and trisomies, mosaicisms, troubles in 
paternal inheritance, presence of genetic variants which induces allelic dropouts, studies 
performed over DNA samples obtained of tissues with paraffin wax, homology locations, 
incorrect identification of locations with high GC content or homopolimeres, and 
reference sequencing mistakes.  
The genetic test is not able neither to identify more than a variant affecting the same 
gene, so it is important to take this fact into account when studying patients who may 
have several recessive disease, which requires both mutated alleles to develop the 
clinical phenotype.  
Each report on a patient's genetic study includes the clinical information of the variant, 
when identified, based on public databases that Health in Code manages with more than 
1 million records from the existing literature on family heart disease and on the center's 
own research, also providing information on carriers and other mutations that may have 
been identified in the same gene. In addition, a bioinformatic study is also included on 
the sequence in which the variant (affected amino acid) is found and information on the 
region and residues, as well as information on the function of the protein that is encoded 
by the gene. 
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As previously mentioned, there are two panels in order to make the genetic HCM test. 
The complete HCM panel includes not only the main sarcomeric genes, but also all the 
disease phenocopies and secondary and candidate genes which are revealed in the 
systematic and current literature review, accounting for 118 genes in the panel (Figure 
19)  In bold print are marked the 17 genes included in the basic panel, which is the first 
approach when studying possibly variants related to the HCM pathogenesis. As can be 
seen, the panel is constituted by 13 genes in which have been found the most part of 
the pathogenic variants directly related to HCM (ACTC1, DES, FHL1, FHOD3, MYBPC3, 
MYH7, MYL2, MYL3, TNNC1, TNNI3, TNNT2, TPM1, TRIM63). 
Usually when addressing a patient with clinical HCM the first genetic step is performing 
a genetic test beginning with the basic 17 genes panel. But once this first genetic test is 
negative and clinically the Cardiologist diagnoses a sure HCM phenotype it, it could be 
useful to perform the complete genetic panel, as this situation improves its profitability. 
There are other situations, as the patient which is diagnosed with a very severe 
phenotype or there is a strong suspicion of hypertrophy myocardiopathy related to 
syndromes or other unusual genetic disease; or when the aim is to perform an 
exhaustive genetic study of this pathology.  
Notwithstanding, in the basic panel it is also possible to find genes associated to other 
specific diseases; PTPN11 is one of the genes whose mutation is related to Noonan 
syndrome, but it is also associated to LEOPARD syndrome; GLA is a gene associated to 
the protein known as Alpha-Galactosidase A, which is the protein affected in Anderson-
Fabry disease, as LAMP2 is the gene whose mutation is related to Danon´s syndrome. 
ACTC1 DES FHL1 FHOD3 GLA LAMP2 MYBPC3 MYH7 MYL2 MYL3 
PRKAG2 PTPN11 TNNC1 TNNI3 TNNT2 TPM1 TRIM63 TTR AARS2 ACAD9 
ACADVL ACTA1 ACTN2 AGK AGL AGPAT2 ALPK3 ATPAF2 BRAF CAV3 
COAS COA6 COQ2 COX15 COX6B1 CSRP3 DLD FAH FHL2 FLNC 
FOXRED1 GAA GFM1 GLB1 GNPTAB GUSB GYG1 HRAS JPH2 KLHL24 
KRAS LIAS LZTR1 MAP2K1 MAP2K2 MLYCD MRPL3 MRPL44 MRPS22 MTO1 
MYOZ2 NF1 NRAS PLN PMM2 RAF1 SCO2 SHOC2 SLC22A5 SLC25A3 
SLC25A4 SOS1 SURF1 TMEM70 AKT1 ANK2 ANKRD1 ATP5F1E BAG3 BSCL2 
C10orf71 CACNA1AC CALR CALR3 CASQ2 CAVIN4 CBL CDH2 CRYAB DSP 
ELAC2 FXN GATA6 KCNJ8 KLF10 LDB3 LMNA MEF2C MYH6 MYLK2 
MYOM1 NEXN PDHA1 PDLIM3 PHKA1 PPA2 PPP1CB QRSL1 RIT1 SOS2 
TAZ TCAP TMOD1 TRIMS4 TSFM TTN VCL WISP1 
Figure 19. Basic and complete HCM genetic panel. Basic panel highlighted in bold writing. Took from 
www.HealthinCode.com  
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Finally, PRKAG2 is related to AMP-gamma2 subunit, which is a protein related to other 
metabolic storage disorder so induces another HCM phenocopy. Finally, the panel also 
includes TTR gene, which is associated to wild-type TTR-related amyloidosis. 1 
It is important to take into account the fact that the proband case is considered to be 
the first family member to be studied, but it is possible he is not the first person in the 
family to be affected by HCM, as there can be family sudden death familiar background 
which was never investigated.  
The study also included the first family member to have suffered sudden cardiac death 
and whose necropsy has shown left or septal ventricular hypertrophy, or another 
phenotype suggestive of HCM, what has led to a genetic study has been carried out from 
a tissue sample of the patient. 
 
 
4. RESULTS 
During the time interval between January 2018 and the first week of January 2020, a 
total of 291 genetic tests were performed in Cantabria in HCM patients. 140 of them 
(48.11%) were performed in proband patients (Figure 20).  
The genetic test using the 
basic Health in Code panel 
results were 88 negative 
studies (62.86%) which 
means there were not 
identified any pathogenic, 
likely pathogenic or with 
unknown significance in 
the genes included in the 
basic panel. 33 studies 
resulted in pathogenic or 
likely pathogenic variants 
(23.57%), as 19 genetic 
tests showed variants of 
unknown significance 
(VUS), accounting for 
13.57% of the studies.   
Demographic and clinical 
characteristics of the 
patients in the study, 
classified depending on 
their genetic tests result 
are described in Table 5.  
There were a majority of men (85), reaching the 60.71% of the probands studied. The 
mean age of the sample was 61.33 years (±1.25). 
Figure 20. Flow chart of the patients´ genetic test performed. US: 
uncertain significance 
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Preserved or normal systolic function, defined as left ventricular ejection fraction (LVEF) 
measured in echocardiography or MRI study upper to 50% but lower than 65% was 
found in 24 patients (72.73%) with pathogenic variants. However, 6 patients (18.18%) 
had hyperdynamic LVEF, defined as an ejection fraction upper to 65%. Three patients 
(9.09%) with pathogenic variant identified had systolic disfunction due to a LVEF lower 
than 50%. The group of patients with VUS in their genetic test result showed 13 (68.42%) 
of them had preserved LVEF, as 6 (31.58%) had hyperdynamic LEVF. There were no 
patients with systolic dysfunction. Finally, 50 patients with non-identified variant in the 
genetic test (56.82%) resulted to have normal LEVF, since 34 (38.64%) even have 
hyperdynamic LVEF. Four patients (4.55%) showed systolic disfunction. 
It is important to remark 50.71% of patients in the study population showed some kind 
of HCM-related symptom, including dyspnea, chest pain, cardiac syncope or 
palpitations. Nineteen of the 33 (57.57%) patients with pathogenic or likely pathogenic 
Table 5. Demographic, clinical, personal and familiar background characteristics of the HCM population studied. 
VUS= variant of uncertain significance; LVEF= left ventricular ejection fraction; BMI= body mass index; SCD= sudden 
cardiac death. 
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variant identified in genetic test were symptomatic at first evaluation; 12 of them 
(36.36%) had dyspnea, defined as NYHA class upper than I2; 2 patients suffered from 
chest pain (6.06%); 4 patients occasionally perceived palpitations (12.12%); whereas 3 
of the patients (9.09%) had a cardiac syncope. Twelve VUS patients also presented any 
kind of symptom (63.15%) related to HCM. 7 patients had any kind of dyspnea (21.21%); 
5 patients had experimented chest pain (15.15%) and 1 patient had ever had palpitations 
(3.03%). In the negative genetic test sample, 29 patients suffered from dyspnea at first 
evaluation (32.95%); 8 had chest pain (9.09%) and 5 admitted having suffered 
palpitations (5.68%). 
Meanwhile, 4 patients (2,86%) were directly first evaluated when they had been 
admitted due to heart failure, what is, when the HCM disease was developed and even 
nearly to end-stage HCM; 2 of them had a pathogenic variant responsible of their LVH. 
One patient (0.71%) included in this study suffered from sudden cardiac death and the 
genetic test was performed from a tissue sample obtained during the necropsy, due to 
the macroscopic confirmation of HCM when performing the autopsy, which resulted to 
be negative. What is more, other variants related to other diseases responsible of 
sudden cardiac death, such as long QT syndrome were not found in the genetic test of 
that patient. 
Fourteen (42.42%) patients carrying a pathogenic or likely pathogenic variant in 
sarcomeric genes where totally asymptomatic. In the same way, 7 (36.84%) patients 
whose genetic test identified a VUS did not present symptoms at first evaluation.  
Taking into account the cardiovascular risk factors the population study presented, it 
was showed 15 of the 33 (45.45%) patients with positive test had arterial hypertension, 
which was similar to the incidence in the VUS, in which 10 (52.63%) suffered from 
arterial hypertension. However, arterial hypertension was present in 65 patients 
(73.86%) with negative study, which means the incidence was higher in the patients with 
negative study. Dyslipemia incidence was similar in VUS and negative study groups, 8 
(42.11%) in the VUS group and 46.59% in patients with negative study, as in the positive 
group was less frequent, accounting for 10 (30.3%) patients suffered from it.  When 
talking about obesity, as 6 patients with positive study had a body mass index (BMI) 
upper to 30 (18.18%), and 3 patients (15.79%) from the VUS group. Nevertheless, 
obesity incidence was higher in the negative study group, accounting for 27.27% of the 
patients.  
Ischemic heart disease was present in 5 patients (15.16%) with pathogenic variants, as 
7 of the 33 (21.21%) patients of that sort also had history of supraventricular arrythmia, 
either paroxysmal or permanent atrial fibrillation or flutter. On the other hand, 4 
patients with VUS (21.05%) suffered from ischemic heart disease, as 3 (15.79%) had 
supraventricular arrythmia background.  
Fifteen and sixteen with negative test study had ischemic heart disease or 
supraventricular arrythmia respectively, representing both 17.05% and 18.18% of the 
sample with no variants identified in the genetic test. Sixty-five patients without variant 
related to HCM identified had arterial hypertension (73.86%), 39 were smokers or 
former smokers (44.32%) 24 suffered from obesity (27.27%), 41 had dyslipemia 
(46.59%). Only 10 patients were diabetic (11.36%). 
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It was shown that 7 (21.21%) of patients who had positive genetic study, also had a first-
degree relative dead due to sudden cardiac death, and 4 had other relatives who had 
suffered sudden cardiac death (12.12%). One patient with VUS had a first degree relative 
and another patient had a non-first degree member (5.26%) dead due to sudden cardiac 
death. The incidence of sudden cardiac death in first degree member in patients with 
negative study (17.05%) was similar to the positive ones, and also in other relatives 
(7.95%). 
Characteristics of the first EKG performed in the patients once HCM is suspected are 
shown in Table 6. 
During the follow-up, in the sample with pathogenic or likely pathogenic variants 
identified were recorded 6 patients with non-sustained or sustained ventricular 
tachycardia (18.18%); also, 6 patients were admitted due to heart failure (18.18%) and 
4 patients suffered from ischemic events (12.12%). Nine patients (27.27%) were selected 
Table 6. Chart with the main characteristics of the first EKG performed in patients from the study 
 36 
to receive an implantable cardioverter-defibrillator, and 4 patients (12.12%) needed a 
pacemaker implant during their evolution.  
All the events during the follow-up are shown in Table 7. Myectomy, known as surgical 
reduction or alcohol ablation, was performed to 2 patients with pathogenic variants 
(6.06%). Heart transplant was only performed to one patient, who also belonged to the 
sample with pathogenic variants identified.  
Three patients with VUS suffered from a non-sustained or sustained ventricular 
tachycardia episode (15.79%). ICD implant was performed in 2 patients of that sample 
(10.53%), and one patient undergone a septal reduction (5.26%). Seven patients with 
non-sustained or sustained ventricular tachycardia episodes were recorded from the 
sample with negative genetic test (7.95%); 6 patients were treated with ICD (6.82%) and 
4 with pacemaker (4.55%). 10 patients were admitted to the hospital due to heart failure 
(11.36%) and 3 patients suffered from ischemic events (3.41%). 
At the time the data collection for this study ended, only 3 patients were dead. One of 
them belonged to the group with pathogenic or likely pathogenic variant identified, and 
the cause of death was a sustained ventricular tachycardia, provoking a sudden cardiac 
death. The other two people did not have any variant related to HCM identified. One of 
them died due to heart failure and the other suffered from sudden cardiac death without 
being identified sustained ventricular tachycardia.  
4.1 GENETIC RESULTS  
Table 8 summarizes the results obtained both in positive studies and the VUS studies. 
MYBPC3 mutation was the most prevalent in the study, present in 14 studies (10% of 
the total genetic test, 42.42% of the positive tests). There were found six missense 
Table 7. Events during follow up in study population. VUS= variant of uncertain significance; NSVT= non-
sustained ventricular tachycardia; SVT= sustained ventricular tachycardia; ICD=implantable cardioverter-
defibrillator 
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variants (42.85%), six truncating variants (42.85%) and two splicing variants (14.29%).  
MYH7 was the second most frequent mutation, as there were 13 studies with variants 
on it (9.28% of the total genetic test and 39.39% of the positive tests). All of the variants 
identified in MYH7 were missense variants (100%).  
MYL3 pathogenic or likely pathogenic variants were also found in two patient’s genetic 
test (1.43% of the total genetic test and 6.06% of the positive tests). Both the variants 
were missense variants (100%).  
FHOD3, TNNI3 and TPM1 were found each in one patient´s results. That means the 
presence of each pathogenic or likely pathogenic variant in those genes supposed the 
0.71% of the genetics test and 3.03% of the positive tests. All of the variants were 
missense variants (100%).  
However, as PLN pathogenic or likely pathogenic variant was also found only in one 
patient, the type of variant that patient carried was a truncating variant. Frequencies of 
the pathogenic mutations found in the study are represented in Figure 21 
Table 8. Chart with the mutations identified in genetic study and number of patients carrying each.  
 38 
Equally important is the analysis of the variants of unknown significance found in the 
genetic test of 19 patients (Figure 22). Once again, MYBPC3 was the most frequent gene 
affected: 7 patients had MYBPC3 variants of uncertain significance (5%). There were 
found 5 patients with VUS in FHOD3 (26.32%). All of them were missense variants. 
FLNC gene presented 2 variants of unknown significance (10.53%); one of the variants 
was a missense variant (50%), but the other type of variant was not conclusive with the 
information available (50%).  
By last, there also were found VUS in GLA, PTPN1, TNNT2, PRKAG2 and MYH7 gene, one 
variant each gene, accounting for 0.71% of the total genetic tests, and 5.26% of the VUS 
genetic tests (each variant).  All of them were missense variants. 
Figure 21. Graphic summarizing the frequencies of pathogenic or likely pathogenic variants found 
in the positive genetic test performed.  
Figure 22. Graphic summarizing the frequencies of VUS found in the genetic test performed.  
 
14 (42.42%)
13 (39.39%)
2 (6.06%)
1 (3.03%)
1 (3.03%)
1 (3.03%) 1 (3.03%)
PATHOGENIC/LIKELY PATHOGENIC VARIANTS 
FREQUENCIES
MYBPC3 MYH7
MYL3 FHOD3
 TNNI3 TPM1
PLN
7 (36.84%)
5 (26.32%)
2 (10.53%)
1 (5.26%)
1 (5.26%)
1 (5.26%)
1 (5.26%) 1 (5.26%)
VUS FREQUENCIES
MYBPC3  FHOD3
FLNC GLA
PTPN11 TNNT2
PRKAG2 MYH7
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5. DISCUSSION  
HCM is the most common monogenic inheritable cardiomyopathy due to sarcomeric 
mutations, with an autosomal dominant pattern. Most cohorts in literature describe it 
is clinically present in 1 of 500 people, and it is defined by left ventricle wall thickness 
greater than 15 mm measured by echocardiography or CMR, which are the main imaging 
tools when diagnosing HCM. 1,8, 11,13, 20 
Pathogenic variants are identified in 60% of patients with HCM, related to abnormal 
myocyte hypertrophy and disarray with fibrosis, resulting in impaired ventricular filling, 
diastolic dysfunction and complications like LVOTO and arrythmias. This may result in a 
wide variety of symptoms, as exertional dyspnea, palpitations or chest pain, although 
many patients could be asymptomatic. Besides, sudden cardiac death is also a risk 
related to HCM, due to abnormalities in heart tissue which may be a substratum for 
arrythmias such ventricular tachycardia. 1, 7, 9 11, 14, 20 
Currently, about 450 mutations in 20 sarcomere and myofilament-related proteins have 
been identified as HCM causes; most of them are in MYH7 and MYBPC3. Genetic test is 
important in order to identify a pathogenic mutation which may confirm HCM and will 
give prognosis information taking into account clinical features too. The identification of 
a pathogenic mutation allows to screen the patient´s relatives before developing 
symptoms and complications. 6, 20 
In this context, this study aims to make an approach about the yield of genetic testing 
HCM patients in Cantabria.  
Sex distribution in the study population corresponds to most of the bibliography in 
which it is accepted that the prevalence of men affected by HCM is approximately 60% 
of the study population. There were no differences between the mean age in the 
patients with positive study (60.97 ± 2.77 years) than the sample with negative genetic 
test (61.40 ± 1.52 years).  
The patients with pathogenic or likely pathogenic variants found also had a lower 
prevalence of the main cardiovascular risk factors related to left ventricle hypertrophy, 
as the arterial hypertension was present in 45.45% of the patients, versus 73.86% of 
patients with no variants identified. This could be attributed to the genetic test was 
profitable when left ventricle hypertrophy studied by imaging test does not correlate to 
the severity or time the patient has been affected by arterial hypertension. 
According to the important family background HCM has, another important fact about 
the proband patients in the study was the presence or absence of familiar past referred 
to sudden cardiac death, accepting also all those sudden unexplained deaths. The first-
degree relative history of sudden cardiac death also was more prevalent in the group 
with pathogenic or likely pathogenic variants (30.43%) compared to the group with 
negative study (17.05%).  
 
MYBPC3 and MYH7 were the most frequent genes affected in pathogenic or likely 
pathogenic variants, involving MYBPC3 the 42.42% of the positive test and MYH7 the 
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39.39%. This means the 81.81% of the genetic test which resulted in a pathogenic or 
likely pathogenic variant, were MYBPC3 and MYH7 the genes involved. It is a little higher 
prevalence than the information found in literature, where the most part of the studies 
support mutations in the MYH7 and MYBPC3 account for about the 75% of the cases. It 
could be explained by the small number of patients of this study comparing large cohorts 
used in the consulted studies. On the other hand, the prevalence isolated of MYBPC3 
and MYH7 is very similar to most cohorts, which show the prevalence of both genes is 
approximately 40% each one.6, 7, 20 
MYBPC3 was also the most frequent gene identified in VUS, and FHOD3 was the second 
most frequent gene, accounting for the 36.84% and 26.32% of the VUS, respectively. 
FHOD3 prevalence in the positive tests of this study (3.03%) was similar to prevalence 
described in literature (1-2%), contrary to FHOD3 VUS prevalence (26.32%), which was 
higher than expected.1, 6, 16 
MYL3 prevalence in cohorts consulted in literature is about 1%. However, in this study a  
prevalence of 6.06% of the pathogenic variants was obtained. 1,6 
TNNT2 is considered in several cohorts as the third or fourth most frequent gene 
affected by mutations in HCM, with a frequency about 10% (5-15%), although in this 
study any pathogenic variant was identified in this gene. 1,6 
The prevalence of pathogenic variants in TPM1 and TNNI3 were similar to the cohorts in 
literature, as TPM1 use to be present in 1-3% of the genetic tests (in this study its 
frequency was 3.03%) and TNNI3 prevalence is about 5% and in this study was 3.03%.1,6 
GLA gene, which is also related to HCM phenocopies such Anderson-Fabry disease 
accounted in the study for the 3.03% of the positive tests, as it is considered to have a 
frequency, together with other HCM phenocopies, of 5-10% of the studies.1 
It is important to remark a pathogenic variant in PLN was identified in one patient, and 
the association between this gene and HCM is very unusual, as it is more frequently 
related to Dilated Cardiomyopathy.2, 10 
Altogether, pathogenic or likely pathogenic variants were found in 7 sarcomere genes, 
as variants of uncertain significance were found in 7 sarcomere genes and one in GLA 
gene, related to Fabry´s disease. The only patient studied with sudden cardiac death 
episode as first manifestation of HCM, did not carry any pathogenic or likely variant, 
neither a variant of uncertain significance. 6 
All patients with positive test had ventricular hypertrophy confirmed by imaging tests 
(echocardiography or CMR). This means 100% of the patients with pathogenic variants 
had septum or some other point of the ventricle thickness ≥ 15 mm. On the other hand, 
20 patients (22.72%) with negative study did not have hypertrophy of the left ventricle 
in the imaging studies. So, the yield of the genetic test could be higher if left ventricle 
hypertrophy has been confirmed at least by one imaging test, what is the genetic test 
should be performed once HCM has been clinically diagnosed in the patient. 
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The study has several limitations. The main one is there is a low number of positive 
studies, making it difficult to draw definitive conclusions. Other limitations in this study 
are the lack of information related to some patients due to the recent creation of a 
department dedicated to familiar Cardiomyopathies, so there are some data that could 
not be recorded, and some information about familiar background has been not 
collected properly. Must also be remembered some symptoms related to HCM could be 
suffered from other disease that provokes the same symptoms, like ischemic chest pain, 
heart failure due to other etiology, as they are certainly unspecific. If the patient suffers 
from cardiovascular disease different from HCM, such chronic ischemic cardiopathy or 
arterial peripheral vascular disease, it would be very challenging to distinguish which of 
the disease caused the symptoms. Nevertheless, the diagnose any heart disease will be 
almost be done simultaneously to HCM. Some clinic diagnoses of HCM were made 
several years ago, even decades, and the genetic test was performed in the interval of 
our data study because it could not be done before. It has been impossible to identify 
all the patients affected from HCM in Cantabria, only those who have been requested a 
genetic test has been taken into account in the study, so the percent of the clinical HCM 
that has been undergone a genetic test has not been possible to be calculated. Data 
collection has been prospective and with limitation in the access to all the information. 
Therefore, the results are only applicable to the HCM population in Cantabria clinically 
diagnosed.  
6. CONCLUSIONS  
 
HCM is the most common inheritable cardiomyopathy. The clinical diagnosis with image 
testing and the estimation of the risk of sudden cardiac death suppose an indispensable 
part of correct managing of the disease. Echocardiography and MRI are the best tests to 
study the patient both at first evaluation and also during the follow-up. It is remarkable 
the importance of making a detailed family tree composed by at least 3 generations as 
part of the first evaluation made when HCM is suspected in a proband patient, which 
means all the suspected HCM should be derived to the familiar Cardiomyopathies 
consultant.  
 
Genetic testing has become one of the main tools in order to approach HCM. Currently 
pathogenic variants can explain about 60% of HCM cases. 1,11, 14, 20 
 
The overall yield of genetic testing using in Cantabria was low, as only 23.57% of the 
patients in the study were identified to carry a pathogenic or likely pathogenic 
mutations, which is lower than most cohorts in literature. The most involved genes were 
variants in MYBPC3 and MYH7. Genetic testing yield is higher when other causes of left 
ventricle hypertrophy, such arterial hypertension, are considered not strong enough to 
provoke such hypertrophy. This also occurs when those other causes of left ventricle 
hypertrophy are discarded studying the ventricle by imaging, such using CMR to 
differentiate athlete´s heart or HCM phenocopies. Familiar background of sudden 
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cardiac death must also be taken into account, as the yield may be higher if there are 
cases of sudden cardiac death in first- degree relatives. 
 
The other pathogenic or likely pathogenic variants found in the study was similar to most 
HCM cohorts. Pathogenic variant in PLN was identified in a patient of the study, which 
is remarkable due to the higher prevalence of pathogenic variants in this gene more 
related to Dilated Cardiomyopathy than to HCM in literature. A variant of uncertain 
significance was identified in GLA gene, which encodes the α-Galactosidase A, being 
responsible of Fabry´s disease, one of the most common HCM phenocopies.  
 
 
Besides, it is important to remark it seems there have been not found yet all the 
pathogenic or likely pathogenic variants related to HCM, which suggests some patients 
with clinical HCM but with no variants identified, may carry mutations in genes not 
discovered or studied as responsible of HCM yet. 
 
 
In conclusion, the prevalence of pathogenic variants found in the genetic test was lower 
than the prevalence described in literature (23.57% versus 60% approximately). All the 
genetic test had ventricle hypertrophy demonstrated by cardiac imaging, but not all the 
patients with negative study (22.73% of the population with negative study) had 
hypertrophy, which means the yield is bigger when HCM is clinically diagnosed with 
hypertrophy developed. However, the conclusions cannot be definitive and 
extrapolated due to the low quantity of data available.  
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